E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Proliferative Vitreoretinopathy |
|
E.1.1.1 | Medical condition in easily understood language |
scar tissue on the retina following retinal detachment |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Ocular Physiological Phenomena [G14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038934 |
E.1.2 | Term | Retinopathy proliferative |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does the use of an additional anti inflammatory agent (ozurdex) given at the time of surgery in patients with established PVR (scar tissue on the retina)result in an improved surgical outcome at 6 months after the surgery? |
|
E.2.2 | Secondary objectives of the trial |
Does the use of an additional anti inflammatory agent (ozurdex) given at the time of surgery in patients with established PVR (scar tissue on the retina)have a positive effect on the following:
1. Visual acuity 6 and 12 months after initial surgery (number of letters read on a standardised vision chart) 2. macula oedema and thickness (the presence of abnormal waterlogging and therefore increased thickness of the most sensitive part of the retina) 3. the development of overt PVR recurrence (whether the scar tissue returns more floridly after surgery 4. complete retinal reattachment (the ability to re attach the entire retina as in some cases this is not possible) 5. stable posterior (post equatorial) retinal reattachment (the ability to reattach the central part of the retina,as in some cases the entire retina cannot be reattached) 6. tractional retinal detachment (the presence of any remaining scar tissue pulling the retina off after surge |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. All patients with established PVR (grade C) following rhegmatogenous retinal detachment requiring surgery. 2. Ability to give informed consent 3. Willingness to accept randomization and attend follow-up. 4. Patients must be over 18 and under 80 years of age. |
|
E.4 | Principal exclusion criteria |
1. Individuals less than 18 years old and older than 80 years old 2. Penetrating intraocular trauma 3. Uncontrolled glaucoma or uveitis 4. Previous steroid induced glaucoma 5. Proliferative Diabetic Retinopathy 6. Pregnant or Breastfeeding females 7. Previous known adverse reaction to the IMP
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Stable retinal reattachment with removal of silicone oil without further vitreoretinal surgical intervention at 6 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 months after initial surgery for proliferative vitreoretinopathy |
|
E.5.2 | Secondary end point(s) |
i) visual acuity (median and ETDRS of 55 letters or better) at 6 and 12 months post op ii) macula oedema and thickness (OCT analysis) iii) development of overt PVR recurrence iv) complete retinal reattachment v) stable posterior (post equatorial) retinal reattachment vi) tractional retinal detachment vii) hypotony/raised IOP viii) macula pucker/epiretinal membrane ix) cataract x) quality of life assessment
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All at 12 months post initial surgical intervention for PVR (with the exception of visual acuity, which will be measured at 6 and 12 months) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
No additional treatment in control group |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial when the last recruited patient attends for their final visit (at 12 months post initial surgery) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 26 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 26 |